Opioid withdrawal syndrome developing after long-term administration of naldemedine.
Palliat Support Care
; 20(6): 897-899, 2022 12.
Article
en En
| MEDLINE
| ID: mdl-35543119
ABSTRACT
OBJECTIVE:
One of the side effects of opioid administration is opioid-induced constipation (OIC). To address this side effect, the oral peripheral µ opioid receptor antagonist naldemedine was developed. As this drug does not cross the blood-brain barrier, it is thought that it does not lead to opioid withdrawal syndrome (OWS) with central nervous system symptoms.METHODS:
Here, we report a cancer patient who presented with symptoms centered round anxiety and irritation 4 months after administration of naldemedine for OIC and who was diagnosed with OWS after close investigation.RESULTS:
The patient was a 65-year-old female who had surgery for stage IB endometrial cancer 4 years previously, but experienced recurrence involving the pelvis 2 years later. Medical narcotics were used to control pain, but naldemedine was started to control subsequent constipation. When naldemedine-related OWS was suspected and the administration of naldemedine discontinued, the above symptoms disappeared within two days, and no recurrence was observed thereafter. SIGNIFICANCE OF THERESULTS:
For patients receiving naldemedine, it is necessary to consider the possibility of OWS regardless of the period of administration in order to maintain patient quality of life.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Calidad de Vida
/
Analgésicos Opioides
Límite:
Aged
/
Female
/
Humans
Idioma:
En
Año:
2022
Tipo del documento:
Article